Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
GLP-1
Pharma
Eisai, Takeda, BIOSECURE Act—Fierce Pharma Asia
Eisai projected a sales increase for Leqembi. Takeda gained an option to license an Alzheimer's therapy. A House committee advanced the BIOSEUCRE Act.
Angus Liu
May 17, 2024 8:30am
Fire breaks out at Novo production hub; none injured
May 16, 2024 11:20am
Takeda, Lilly-Innovent, BIO-China—Fierce Pharma Asia
May 10, 2024 9:30am
Real Chemistry data dashboard tracks rise of 'GLP-1 influencer'
May 2, 2024 7:30am
Lilly: Zepbound, Mounjaro supply to remain tight through 2024
Apr 30, 2024 12:03pm
Is AstraZeneca stretching too thin with M&As? CEO says 'no'
Apr 25, 2024 11:09am